Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07329640 Monotherapy and Combination in Advanced Solid Tumors
NCT06448364Phase 1Terminated
- Sponsor
- Pfizer
- Start
- May 2024
- Primary completion
- Aug 2024
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Countries
- 2
01
Overview
Phase 1, open-label trial of PF-07329640 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 2 more (7 arms), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities at 28 days, Adverse Events and 2 more. Started May 2024; status: terminated.
02
Drugs
PF-07329640
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)urothelial carcinoma (UC)melanoma
Beyond the preview
Go deeper on NCT06448364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06448364.